
KNW Stock Forecast & Price Target
KNW Analyst Ratings
Bulls say
Know Labs, Inc. operates within a rapidly growing healthcare system, which experienced a significant increase from $245 billion in 2012 to $327 billion in 2017, reflecting a 26% growth over five years, equating to a 6% compound annual growth rate (CAGR). The company's innovative Bio-RFID and ChromaID technologies, particularly the development of a non-invasive blood glucose monitoring wearable device, position it to capture unmet market needs, especially given the renewed focus on metabolism and weight management. Furthermore, the potential revenue streams from international markets and non-insulin-using Type 2 diabetes patients present substantial growth opportunities that are not currently accounted for in profit expectations, indicating a positive outlook for future financial performance.
Bears say
Know Labs Inc. has faced persistent operating losses since its inception, raising concerns about its potential to achieve profitability in the near future. Additionally, the company faces significant competitive pressures from existing therapies and procedures that could hinder product adoption and overall performance. The negative sentiment surrounding Know Labs is compounded by the emergence of GLP-1 agonists, which may reduce the patient population for diabetes management, further impacting the company's market prospects.
This aggregate rating is based on analysts' research of Know Labs Inc and is not a guaranteed prediction by Public.com or investment advice.
KNW Analyst Forecast & Price Prediction
Start investing in KNW
Order type
Buy in
Order amount
Est. shares
0 shares